Table of contents
Volume 100, Issue 2
Published online 22 January 2009 (221-430)
Minireviews |
Clinical Studies |
Translational Therapeutics |
Molecular Diagnostics |
Genetics and Genomics
Minireview
Normal stem cells in cancer prone epithelial tissues FREE
T J Phesse and A R Clarke
Br J Cancer 100: 221-227; advance online publication, January 6, 2009; doi:10.1038/sj.bjc.6604850
Minireviews
The spliceosome as target for anticancer treatment FREE
R J van Alphen, E A C Wiemer, H Burger and F A L M Eskens
Br J Cancer 100: 228-232; advance online publication, November 25, 2008; doi:10.1038/sj.bjc.6604801
Folate and colorectal cancer prevention FREE
R A Hubner and R S Houlston
Br J Cancer 100: 233-239; advance online publication, December 16, 2008; doi:10.1038/sj.bjc.6604823
Concepts of epigenetics in prostate cancer development FREE
C S Cooper and C S Foster
Br J Cancer 100: 240-245; advance online publication, November 11, 2008; doi:10.1038/sj.bjc.6604771
Clinical Studies
Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials FREE
J P Neoptolemos, D D Stocken, C Tudur Smith, C Bassi, P Ghaneh, E Owen, M Moore, R Padbury, R Doi, D Smith and M W Büchler for the European Study Group of Pancreatic Cancer
Br J Cancer 100: 246-250; advance online publication, January 6, 2009; doi:10.1038/sj.bjc.6604838
Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience FREE
R A Adams, A M Meade, A Madi, D Fisher, E Kay, S Kenny, R S Kaplan and T S Maughan on behalf of the COIN trial TMG and investigators
Br J Cancer 100: 251-258; doi:10.1038/sj.bjc.6604877
Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? FREE
G Grazzini, C B Visioli, M Zorzi, S Ciatto, F Banovich, A G Bonanomi, A Bortoli, G Castiglione, L Cazzola, M Confortini, P Mantellini, T Rubeca and M Zappa
Br J Cancer 100: 259-265; advance online publication, January 13, 2009; doi:10.1038/sj.bjc.6604864
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer FREE
M Koopman, G A M Kortman, L Mekenkamp, M J L Ligtenberg, N Hoogerbrugge, N F Antonini, C J A Punt and J H J M van Krieken
Br J Cancer 100: 266-273; doi:10.1038/sj.bjc.6604867
Development and pilot evaluation of a complex intervention to improve experienced continuity of care in patients with cancer FREE
M King, L Jones, O McCarthy, M Rogers, A Richardson, R Williams, A Tookman and I Nazareth
Br J Cancer 100: 274-280; advance online publication, December 23, 2008; doi:10.1038/sj.bjc.6604836
Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan FREE
M Kondo, S-L Hoshi and M Toi
Br J Cancer 100: 281-290; advance online publication, January 13, 2009; doi:10.1038/sj.bjc.6604869
A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer FREE
T Neuhaus, Y Ko, R P Muller, G G Grabenbauer, J P Hedde, H Schueller, M Kocher, S Stier and R Fietkau
Br J Cancer 100: 291-297; advance online publication, January 6, 2009; doi:10.1038/sj.bjc.6604835
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer FREE
S-W Han, D-Y Oh, S-A Im, S R Park, K-W Lee, H S Song, N-S Lee, K H Lee, I S Choi, M H Lee, M A Kim, W H Kim, Y-J Bang and T-Y Kim
Br J Cancer 100: 298-304; advance online publication, January 6, 2009; doi:10.1038/sj.bjc.6604861
A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer FREE
R L Jones, G Walsh, S Ashley, S Chua, R Agarwal, M O'Brien, S Johnston and I E Smith
Br J Cancer 100: 305-310; doi:10.1038/sj.bjc.6604862
Translational Therapeutics
Direct effects of doxorubicin on skeletal muscle contribute to fatigue FREE
K van Norren, A van Helvoort, J M Argilés, S van Tuijl, Karin Arts, M Gorselink, A Laviano, D Kegler, H P Haagsman and E M van der Beek
Br J Cancer 100: 311-314; advance online publication, January 13, 2009; doi:10.1038/sj.bjc.6604858
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours FREE
M Campone, V Levy, E Bourbouloux, D Berton Rigaud, D Bootle, C Dutreix, U Zoellner, N Shand, F Calvo and E Raymond
Br J Cancer 100: 315-321; advance online publication, January 6, 2009; doi:10.1038/sj.bjc.6604851
Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53 FREE
S C Naumann, W P Roos, E Jöst, C Belohlavek, V Lennerz, C W Schmidt, M Christmann and B Kaina
Br J Cancer 100: 322-333; advance online publication, January 6, 2009; doi:10.1038/sj.bjc.6604856
Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin FREE
X Wu, A Wanders, P Wardega, B Tinge, L Gedda, S Bergstrom, L Sooman, J Gullbo, M Bergqvist, P Hesselius, J Lennartsson and S Ekman
Br J Cancer 100: 334-343; advance online publication, January 13, 2009; doi:10.1038/sj.bjc.6604855
Molecular Diagnostics
Promoter CpG methylation in cancer cells contributes to the regulation of MUC4 FREE
N Yamada, Y Nishida, H Tsutsumida, M Goto, M Higashi, M Nomoto and S Yonezawa
Br J Cancer 100: 344-351; advance online publication, January 6, 2009; doi:10.1038/sj.bjc.6604845
Loss of the coxsackie and adenovirus receptor contributes to gastric cancer progression FREE
M Anders, M Vieth, C Röcken, M Ebert, M Pross, S Gretschel, P M Schlag, B Wiedenmann, W Kemmner and M Höcker
Br J Cancer 100: 352-359; advance online publication, January 13, 2009; doi:10.1038/sj.bjc.6604876
CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients FREE
J Harder, V Engelstaedter, H Usadel, S Lassmann, M Werner, P Baier, F Otto, M Varbanova, E Schaeffner, M Olschewski, H E Blum and O G Opitz
Br J Cancer 100: 360-365; advance online publication, January 13, 2009; doi:10.1038/sj.bjc.6604859
A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45 FREE
G Descamps, P Gomez-Bougie, C Venot, P Moreau, R Bataille and M Amiot
Br J Cancer 100: 366-369; doi:10.1038/sj.bjc.6604839
Genetics and Genomics
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition FREE
C L Mahoney, B Choudhury, H Davies, S Edkins, C Greenman, G van Haaften, T Mironenko, T Santarius, C Stevens, M R Stratton and P A Futreal
Br J Cancer 100: 370-375; doi:10.1038/sj.bjc.6604886
The G67E mutation in hMLH1 is associated with an unusual presentation of Lynch syndrome FREE
M Clyne, J Offman, S Shanley, J D Virgo, M Radulovic, Y Wang, A Ardern-Jones, R Eeles, E Hoffmann and V P C C Yu
Br J Cancer 100: 376-380; advance online publication, January 13, 2009; doi:10.1038/sj.bjc.6604860
Nuclear oxidative damage correlates with poor survival in colorectal cancer FREE
J Sheridan, L-M Wang, M Tosetto, K Sheahan, J Hyland, D Fennelly, D O'Donoghue, H Mulcahy and J O'Sullivan
Br J Cancer 100: 381-388; advance online publication, December 9, 2008; doi:10.1038/sj.bjc.6604821
Cross talk between hedgehog and epithelial–mesenchymal transition pathways in gastric pit cells and in diffuse-type gastric cancers FREE
H Ohta, K Aoyagi, M Fukaya, I Danjoh, A Ohta, N Isohata, N Saeki, H Taniguchi, H Sakamoto, T Shimoda, T Tani, T Yoshida and H Sasaki
Br J Cancer 100: 389-398; advance online publication, December 23, 2008; doi:10.1038/sj.bjc.6604846
RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker FREE
A Misawa, S Tanaka, S Yagyu, K Tsuchiya, T Iehara, T Sugimoto and H Hosoi
Br J Cancer 100: 399-404; doi:10.1038/sj.bjc.6604887
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy FREE
E Y Tan, M Yan, L Campo, C Han, E Takano, H Turley, I Candiloro, F Pezzella, K C Gatter, E K A Millar, S A O'Toole, C M McNeil, P Crea, D Segara, R L Sutherland, A L Harris and S B Fox
Br J Cancer 100: 405-411; doi:10.1038/sj.bjc.6604844
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium FREE
C L Pearce, A M Near, D J Van Den Berg, S J Ramus, A Gentry-Maharaj, U Menon, S A Gayther, A R Anderson, C K Edlund, A H Wu, X Chen, J Beesley, P M Webb, S K Holt, C Chen, J A Doherty, M A Rossing, A S Whittemore, V McGuire, R A DiCioccio, M T Goodman, G Lurie, M E Carney, L R Wilkens, R B Ness, K B Moysich, R Edwards, E Jennison, S K Kjaer, E Hogdall, C K Hogdall, E L Goode, T A Sellers, R A Vierkant, J C Cunningham, J M Schildkraut, A Berchuck, P G Moorman, E S Iversen, D W Cramer, K L Terry, A F Vitonis, L Titus-Ernstoff, H Song, P D P Pharoah, A B Spurdle, H Anton-Culver, A Ziogas, W Brewster, V Galitovskiy, G Chenevix-Trench, Australian Cancer Study (Ovarian Cancer)Australian Ovarian Cancer Study Group on behalf of the Ovarian Cancer Association Consortium
Br J Cancer 100: 412-420; advance online publication, January 6, 2009; doi:10.1038/sj.bjc.6604820
Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation FREE
K A Metcalfe, A Finch, A Poll, D Horsman, C Kim-Sing, J Scott, R Royer, P Sun and S A Narod
Br J Cancer 100: 421-425; advance online publication, December 16, 2008; doi:10.1038/sj.bjc.6604830
A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer FREE
Z Kote-Jarai, S Jugurnauth, S Mulholland, D A Leongamornlert, M Guy, S Edwards, M Tymrakiewitcz, L O'Brien, A Hall, R Wilkinson, A A Al Olama, J Morrison, K Muir, D Neal, J Donovan, F Hamdy, D F Easton, The UKGPCS Collaborators, The British Association of Urological Surgeons' Section of OncologyR Eeles
Br J Cancer 100: 426-430; advance online publication, January 6, 2009; doi:10.1038/sj.bjc.6604847
The published online date indicates the date that the issue is published online and is the first official publication date of the issue. Each print issue of BJC is published one week after it has been published online.
